Phase 2 Trial

ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has screened the first patient in its Phase 2b dose-ranging study of eblasakimab (ASLAN004) in adults with moderate-to-severe atopic dermatitis (AD).  Eblasakimab is a monoclonal antibody targeting the IL-13 receptor.  ASLAN expects...

Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has dosed the first patient in Phase 2 trial of OPNT002, nasal naltrexone, for Alcohol Use Disorder (AUD).  The trial will determine whether OPNT002 reduces heavy drinking as measured by a change in the World Health Organization (WHO)...

The FDA has signed off Turning Point Therapeutics Inc's (NASDAQ: TPTX) Investigational New Drug (IND) application for elzovantinib + aumolertinib combo therapy in EGFR mutant MET-amplified advanced non-small cell lung cancer (NSCLC).  The Company expects to initiate the...

The FDA has signed off Compass Therapeutics Inc's (NASDAQ: CMPX) IND application for CTX-009 to initiate a global Phase 2 clinical trial for CTX-009 for advanced Biliary Tract Cancers (BTC) in the U.S. and South Korea.  The Company plans to include the existing Phase 2 in...

The FDA has signed off Nuvation Bio Inc's (NYSE: NUVB) investigational new drug (IND) application to evaluate NUV-868 to treat advanced solid tumors. NUV-868 inhibits BRD4, a key member of the BET family that epigenetically regulates proteins that control tumor growth and...

KemPharm Inc (NASDAQ: KMPH) has selected KP1077 for idiopathic hypersomnia (IH) as its lead serdexmethylphenidate (SDX) candidate in the pipeline. Idiopathic hypersomnia is an uncommon sleep disorder resulting in chronic excessive daytime sleepiness. Issuing a letter to shareholders, CEO...

Leap Therapeutics Inc (NASDAQ: LPTX) will present updated data from the DisTinGuish Phase 2a study of DKN-01, in combination with tislelizumab in gastric or gastric gastroesophageal junction cancer (G/GEJ). Data will be shared at the American Society of Clinical Oncology Gastrointestinal...

Cardiff Oncology Inc (NASDAQ: CRDF) posted new data from Phase 1b/2 trial of onvansertib combined with standard-of-care (SOC) FOLFIRI/bevacizumab for second-line KRAS-mutated metastatic colorectal cancer (mCRC). The data will be shared at the American Society of Clinical Oncology...

RedHill Biopharma Ltd (NASDAQ: RDHL) announced new data from a prespecified analysis of all oral opaganib's Phase 2/3 study patients in COVID-19 patients. The data demonstrated that opaganib improved the median time to viral RNA clearance by at least four days.  Treatment...

Vaxcyte Inc (NASDAQ: PCVX) priced its previously announced offering of common stock and pre-funded warrants at $20.00 per share, and $19.999 per underlying share, respectively. Vaxcyte is selling 2.5 million shares and pre-funded warrants to purchase 2.5 million shares of common...

Ocugen Inc (NASDAQ: OCGN) announced that a booster shot of the COVID-19 vaccine candidate generated over a 10-fold increase in antibody levels across a range of coronavirus variants. Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Ocugen said...

Longeveron Inc (NASDAQ: LGVN) has initiated its Phase 2a clinical trial evaluating Lomecel-B for Alzheimer’s disease (AD). The first patient has consented to participate in the trial, and patient screening has begun. What Happened: The Phase 2a study intends to build on encouraging...

Annexon Inc (NASDAQ: ANNX) posted interim data from its ongoing Phase 2 trial of ANX005 in patients with Huntington's disease (HD) who completed the 24-week treatment period.  Annexon is developing ANX005, its lead monoclonal antibody candidate, for a range of complement-...

The University of Alabama at Birmingham (UAB) and Mereo BioPharma Group plc (NASDAQ: MREO) announced topline data from a Phase 1b/2 trial of alvelestat in hospitalized COVID-19 Respiratory Disease patients. Consistent with the known safety profile of alvelestat, no safety...

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) is voluntarily ending its Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertension (PAH). The decision follows COVID-19 impacts on manufacturing, associated drug supply, and enrollment rate in the study.  The...